

1 **Prospective validation of host transcriptomic biomarkers for pulmonary** 2 **tuberculosis by real-time PCR**

3
4 Simon C. Mendelsohn, MBChB¹, Stanley Kimbung Mbandi, PhD¹, Andrew Fiore-Gartland, PhD²,
5 Adam Penn-Nicholson, PhD¹, Munyaradzi Musvosvi, PhD¹, Humphrey Mulenga, MPH¹, Michelle
6 Fisher, PhD¹, Katie Hadley, PhD¹, Mzwandile Erasmus, BSc¹, Onke Nombida, GT¹, Michèle
7 Tameris, MBChB¹, Gerhard Walzli, MBChB³, Kogieleum Naidoo, PhD^{4,5}, Gavin Churchyard,
8 PhD^{6,7,8}, Mark Hatherill, MD¹, Thomas J. Scriba, DPhil¹, The Cross-sectional TB Cohort Study
9 Team*, and The CORTIS Study Team*

10

11 ¹South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular
12 Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, 7925,
13 Cape Town, South Africa.

14 ²Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA
15 98109, USA.

16 ³DST/NRF Centre of Excellence for Biomedical TB Research; South African Medical Research
17 Council Centre for TB Research; Division of Molecular Biology and Human Genetics, Department
18 of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, 7505,
19 Cape Town, South Africa.

20 ⁴Centre for the AIDS Programme of Research in South Africa (CAPRISA), 4001, Durban, South
21 Africa.

22 ⁵MRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Doris Duke Medical
23 Research Institute, University of KwaZulu-Natal, 4001, Durban, South Africa.

24 ⁶The Aurum Institute, 2194, Johannesburg, South Africa.

25 ⁷School of Public Health, University of Witwatersrand, 2193, Johannesburg, South Africa.

26 ⁸Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA.

27

28 * See supplement

29

30 **Word count:** 6,821 words (48,585 characters including spaces)

31 **Running title:** Blood mRNA biomarkers for pulmonary TB

32

33 **Corresponding author:** Thomas J Scriba

34 **Email:** Thomas.Scriba@uct.ac.za **Telephone:** +27 (0) 21 406 6427

35 **Postal address:** South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and
36 Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town,
37 Anzio Road, Observatory, 7925, Cape Town, South Africa

38 **Abstract**

39 We tested performance of host-blood transcriptomic tuberculosis (TB) signatures for active case-
40 finding. Among 20,207 HIV-uninfected and 963 HIV-infected adults screened; 2,923 and 861 were
41 enrolled from five South African communities. Eight signatures were measured by microfluidic RT-
42 qPCR and participants were microbiologically-investigated for pulmonary TB at baseline, and
43 actively surveilled for incident disease through 15 months. Diagnostic AUCs for 61 HIV-uninfected
44 (weighted-prevalence 1.1%) and 10 HIV-infected (prevalence 1.2%) prevalent TB cases for the 8
45 signatures were 0.63–0.79 and 0.65–0.88, respectively. Thereafter, 24 HIV-uninfected and 9 HIV-
46 infected participants progressed to incident TB (1.1 and 1.0 per 100 person-years, respectively).
47 Prognostic AUCs through 15-months follow-up were 0.49–0.66 and 0.54–0.81, respectively.
48 Prognostic performance for incident TB occurring within 6-12 months in HIV-negative participants
49 was higher for all signatures. None of the signatures met WHO Target Product Profile criteria for a
50 triage test to diagnose asymptomatic TB; most signatures met the criteria for symptomatic TB.
51 Prognostic accuracy of most signatures for incident TB within six months of testing met the criteria
52 for an incipient TB test.

53

54 *Keywords*

55 Diagnostic / prognostic/ transcriptional / signature / Tuberculosis

56 Introduction

57 An estimated 2.9 million people with tuberculosis (TB) disease went undiagnosed or unreported in
58 2019¹, partly because passive case-finding strategies rely primarily on self-presentation of people
59 for healthcare when they experience TB symptoms, and dependence on sputum for
60 microbiological testing. TB prevalence surveys in Africa and Asia demonstrate that approximately
61 50% of TB cases are asymptomatic, highlighting a major blind-spot in the symptom-dependent
62 case-finding strategies, which may perpetuate significant *Mycobacterium tuberculosis* (*Mtb*)
63 transmission.²⁻⁵ Currently available triage tests and passive case-finding strategies for symptomatic
64 disease are thus inadequate to find these missing cases among people who do seek healthcare.
65 Effective active case-finding tools for screening of asymptomatic individuals in the community are
66 urgently needed for earlier detection, further microbiological testing, and treatment, in order to
67 interrupt the spread of *Mtb*.

68

69 Computer-aided detection for automated interpretation of digital chest radiographs⁶ is one such
70 approach for rapid and cheap mass screening, particularly in resource-constrained settings. Mobile
71 sputum Xpert MTB/RIF screening also performs well as a community-based case-finding strategy,
72 but requires significant resources and is dependent on availability of a sputum sample.⁷ Tests for
73 detection of *Mtb*-exposed individuals at high risk of progression to TB disease, particularly in high
74 burden settings, are also urgently needed to guide TB preventive therapy (TPT). Interferon- γ
75 release assays (IGRA) and tuberculin skin testing lack specificity in endemic settings due to high
76 rates of prior *Mtb* exposure, which result in both overtreatment of those unlikely to progress to
77 disease and missed “incipient” cases.⁸ IGRA are also laborious, and require laboratory facilities
78 and skilled technicians.

79

80 We previously developed a predictive correlate of risk signature, RISK11, for diagnosis of TB
81 disease and for identification of individuals at high risk of progression to active TB disease.^{9,10}
82 Diagnostic and prognostic performance of RISK11 as a PCR-based screening test was
83 prospectively validated in HIV-uninfected adults¹¹ and people living with HIV (PLHIV)¹². This
84 signature is not ideal for further development due to its large size (48 primer-probe assays).
85 Fortunately, several refined, parsimonious diagnostic and prognostic transcriptomic signatures,
86 which are more amenable to translation to point-of-care testing, have been developed.¹³⁻¹⁶
87 However, most transcriptomic signature discovery and validation studies use a case-control design
88 with stringent exclusion criteria, resulting in spectrum bias and best-case discriminative
89 performance, which is not reproducible in prospective studies in heterogenous real-world settings.
90 Transcriptomic signatures are predominantly measured by microarray or RNA-sequencing,
91 techniques which are not suitable for use at the point of care. There are also few studies which
92 have performed unbiased head-to-head comparisons of signature performance¹³⁻¹⁵ and none for

93 active case-finding in a community setting. It is therefore not clear which, if any, signatures offer
94 potential in this context and should be advanced along the developmental pipeline.

95

96 We recently showed that HIV and upper respiratory tract viruses result in an increase in RISK11
97 score and hypothesised that this was due to the upregulation of interferon-stimulated genes (ISG)
98 as part of an inflammatory response typically induced in TB and viral infections.^{10,12,17} Further,
99 RISK11 was able to differentiate individuals with TB disease from those with bacterial or no upper
100 respiratory tract microorganisms, but was not able to discriminate between those with TB from
101 those with upper respiratory tract viruses. Most TB transcriptomic signatures primarily detect
102 elevated ISG expression. The effect of HIV and respiratory viruses on scores and performance of
103 these other signatures, including those which do not encompass ISGs such as the Thompson5
104 (RESPONSE5) signature¹⁸, has not been adequately explored.

105

106 In this paper we report the results of a multi-centre observational study, which prospectively tested
107 the performance of eight parsimonious host-blood TB transcriptomic signatures measured by
108 microfluidic real-time (RT) qPCR, for diagnosing prevalent pulmonary TB and predicting
109 progression to incident TB disease, in a predominantly asymptomatic community cohort of HIV-
110 uninfected and HIV-infected South African adults. As secondary aims, we compared signature
111 diagnostic performance in symptomatic and asymptomatic participants, and benchmarked
112 parsimonious signature accuracy against RISK11 and the World Health Organization (WHO)
113 Target Product Profile (TPP) criteria for triage and prognostic TB tests.^{19,20} As an exploratory aim,
114 we also explored the effect of HIV and upper respiratory tract microorganisms on transcriptomic
115 signature scores.

116 **Methods**

117

118 *Study design and participants*

119 In this diagnostic and prognostic accuracy study, we evaluated parsimonious blood-based host
120 transcriptomic signature performance in four South African cohorts (**Figure S1**). We first translated
121 the signatures to a RT-qPCR platform and validated performance in a case-control study of HIV-
122 uninfected and HIV-infected individuals with and without pulmonary TB, the Cross-sectional TB
123 Cohort (CTBC) study (**Figure S1A**). We then prospectively tested signature performance in HIV-
124 uninfected volunteers enrolled in the CORTIS-01 trial (ClinicalTrials.gov: NCT02735590; **Figure**
125 **S1B**) and PLHIV enrolled in the observational CORTIS-HR study (**Figure S1D**). Finally, we
126 evaluated the effects of upper respiratory microorganisms on transcriptomic signatures in a subset
127 of HIV-uninfected participants screened for the CORTIS-01 trial (**Figure S1C**). This study is
128 reported in accordance with the Standards for Reporting Diagnostic Accuracy Studies initiative
129 guidelines²¹ and the study protocol was approved by the University of Cape Town Faculty of
130 Health Sciences Human Research Ethics Committee (HREC 812/2017). Written informed consent
131 was obtained from all participants and all experiments conformed to the principles set out in the
132 WMA Declaration of Helsinki and the US Department of Health and Human Services Belmont
133 Report.

134

135 *Cross-sectional TB Cohort*

136 The CTBC case-control study was previously described.²² Briefly, adults aged ≥ 18 years with
137 newly diagnosed pulmonary TB confirmed by sputum Xpert MTB/RIF (Cepheid, Sunnyvale, CA,
138 USA) and/or liquid mycobacterial culture (Mycobacteria Growth Indicator Tube [MGIT], BACTEC,
139 Beckton Dickinson, Franklin Lakes, NJ, USA) were enrolled at primary healthcare clinics in
140 Worcester and Masiphumelele, South Africa. Healthy, asymptomatic community controls were
141 recruited from the same areas. HIV-infection was diagnosed with the Determine HIV1/2 test (Aler,
142 Waltham, MA, USA). All participants provided written, informed consent and the protocols were
143 approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics
144 Committee (HREC 126/2006 and 288/2008).

145

146 *Correlate of Risk Targeted Intervention Study (CORTIS)*

147 The CORTIS-01 clinical trial in HIV-uninfected individuals and CORTIS-HR observational study in
148 PLHIV have previously been described.^{11,12} Briefly, healthy adult volunteers without clinical
149 suspicion of TB, residing in five TB endemic communities in South Africa (Durban, Klerksdorp,
150 Ravensmead, Rustenburg, and Worcester), were recruited through word-of-mouth, house-to-
151 house visits, and liaison with non-governmental organisations. Recruitment did not target
152 symptomatic individuals seeking health care or other high-risk groups. Eligible participants aged
153 18–59 years were without comorbidities (except for HIV) and did not have known TB disease, or

154 household exposure to individuals with multi-drug resistant TB, within the prior three years. The
155 RISK11 signature was measured at enrolment, and a pre-specified score threshold of 60% was
156 used to differentiate RISK11-positive from RISK11-negative participants. The HIV-uninfected
157 CORTIS-01 population was enriched for participants at high risk of TB disease through enrolment
158 of all eligible RISK11-positive individuals, and randomisation of RISK11-negative participants to
159 enrolment or non-enrolment at a 1:7-9 ratio. RISK11-positive participants were randomised to
160 receive TPT (weekly high-dose isoniazid and rifapentine for three months, 3HP) or no intervention;
161 RISK11-negative participants were randomised to no intervention or excluded from the study. In
162 the CORTIS-HR observational study, PLHIV were enrolled irrespective of RISK11 status and
163 referred for standard of care antiretroviral and isoniazid preventive therapy.

164

165 All CORTIS participants provided two spontaneously expectorated sputum samples at enrolment
166 and at the end of study visits. End of study visits were performed at month 15 of follow-up or at an
167 earlier timepoint for withdrawn participants. Both samples collected at enrolment from HIV-
168 uninfected participants (CORTIS-01) were tested for *Mtb* using Xpert MTB/RIF, and from HIV-
169 infected participants (CORTIS-HR) using Xpert MTB/RIF and MGIT culture. The two samples
170 collected at the end of study visit were tested using Xpert MTB/RIF or Xpert Ultra (Cepheid), and
171 MGIT culture. In addition, symptom-triggered TB investigations (two sputum samples; one for
172 Xpert MTB/RIF and one for MGIT culture) were performed at six routine study visits through 15-
173 months follow-up. TB symptoms included at least one of: persistent unexplained cough, night
174 sweats, fever, or weight loss for 2 weeks or more, or any haemoptysis. Participants diagnosed with
175 microbiologically-confirmed TB were withdrawn from the study and referred for curative treatment.
176 All participants provided written informed consent and study protocols were approved by the
177 institutional human research ethics committees of the five participating sites.

178

179 *Respiratory pathobionts cohort*

180 The respiratory pathobionts cohort, a subset of participants screened for eligibility for the CORTIS-
181 01 trial at the Worcester site, has previously been described.¹⁷ Pathobionts encompass pathogenic
182 and commensal microorganisms. Briefly, HIV-uninfected participants were consecutively enrolled
183 in this sub-study irrespective of CORTIS-01 enrolment, or signs and symptoms of upper respiratory
184 tract infections. Paired nasopharyngeal and oropharyngeal flocced swabs (FLOQSwabs, Copan
185 Diagnostics, Murrieta, CA, USA) were collected and stored in Primestore buffer (Longhorn
186 Vaccines and Diagnostics, San Antonio, TX, USA) at -80°C, and viral and bacterial nucleic acid
187 was later extracted (Qiasymphony Virus/Bacteria Mini Kit, Qiagen, Hilden, Germany) and
188 quantified using a multiplex RT-qPCR assay kit (Respiratory Pathogens 33 Kit, Fast Track
189 Diagnostics, Luxembourg) on the CFX96 Touch System lightcycler platform (Bio-Rad, Hercules,
190 CA, USA), according to the manufacturer's instructions. Participants co-enrolled into the CORTIS-
191 01 trial were investigated for TB at baseline; those only enrolled into the respiratory pathobionts

192 cohort were not investigated for TB (**Figure S1C**). All participants provided written, informed
193 consent and the protocols were approved by the University of Cape Town Faculty of Health
194 Sciences Human Research Ethics Committee (HREC 327/2017).

195

196 *Blood sample collection and RNA extraction*

197 Venous whole blood was collected in PAXgene tubes (PreAnalytiX, Hombrechtikon, Switzerland)
198 at enrolment in all cohorts, frozen at -20°C, and shipped to the South African Tuberculosis Vaccine
199 Initiative (SATVI) Cape Town laboratory. For the CTBC study, RNA was manually extracted with
200 the PAXgene blood RNA kit (Qiagen) according to the manufacturer's instructions, stored at -80
201 °C, and later used for transcriptomic analysis. For the other cohorts, RNA was extracted using a
202 high-throughput, standardised, and reproducible fully automated procedure on the Freedom EVO
203 150 robotic platform (Tecan, Männedorf, Switzerland) with the Maxwell SimplyRNA kit (Promega,
204 Madison, WI, USA). One aliquot of RNA was used immediately for cDNA synthesis and
205 measurement of the RISK11 signature, and a second aliquot was stored at -80 °C, and later used
206 to measure the panel of parsimonious transcriptomic signatures.

207

208 *Measurement of TB transcriptomic signatures*

209 Eight parsimonious diagnostic, prognostic, and treatment response host-blood TB transcriptomic
210 signatures were pragmatically selected for inclusion in this head-to-head validation alongside
211 RISK11 based on availability of validated performance data, number of transcripts (six or fewer),
212 and availability of target sequences for custom primer-probe design or predesigned TaqMan
213 assay. As a naming convention, we use the first author and number of genes included in the
214 signature: Francisco2²³, Maertzdorf4²⁴ (also known as DIAG4), Penn-Nicholson6 (also known as
215 RISK6)²², Suliman4 (also known as RISK4)²⁵, Roe1²⁶ (BATF2 only), Roe3²⁷, Sweeney3²⁸, and
216 Thompson5¹⁸ (also known as RESPONSE5). The Herberg2 signature²⁹, designed to discriminate
217 between viral and bacterial infection in febrile children, was also included as a potential
218 discriminator between viral and mycobacterial infection in the respiratory pathobionts cohort.
219 Signatures were measured and scores calculated as previously reported (**Tables S1-S6**).

220

221 Following cDNA-synthesis with EpiScript reverse transcriptase (Lucigen, Middleton, WI, USA),
222 genes of interest (**Tables S2-S3**) were pre-amplified using pools of TaqMan primer-probe assays
223 (Thermo Fisher Scientific, Waltham, MA, USA), and gene expression (raw cycle threshold, Ct)
224 quantified by microfluidic multiplex RT-qPCR using either Fluidigm (San Francisco, CA, USA)
225 96.96 (96 samples multiplexed with 96 primer-probe assays) or 192.24 (192 samples multiplexed
226 with 24 primer-probe assays) Gene Expression chips on the BioMark HD instrument (Fluidigm).
227 Further details regarding primer-probe assay selection and qualification, data quality control, and
228 signature score measurement are provided in the **Supplemental Methods**.

229

230

231 *Endpoints*

232 For the CTBC study and respiratory pathobionts sub-study, TB disease was defined by a single
233 sputum sample positive for *Mtb* on either Xpert MTB/RIF and/or liquid culture at enrolment. The
234 coprimary endpoints in the CORTIS studies were baseline prevalent TB disease and incident
235 disease through 15 months follow-up confirmed by a positive Xpert MTB/RIF, Xpert Ultra, or MGIT
236 culture, on two or more separate sputum samples collected within any 30-day period. The
237 secondary endpoint was microbiologically-confirmed TB disease on at least one sputum sample.
238 All Xpert Ultra trace positive results were excluded from the analysis because of the risk of false
239 positives.

240

241 *Statistical analyses*

242 The statistical analysis plan for the CORTIS sub-studies was pre-specified (**Appendix p20**) and all
243 statistical analyses were done in R (Boston, MA, USA), version 3.6.1. Sample sizes for this sub-
244 study were not pre-specified, but were based on accumulated enrolment of the CTBC and CORTIS
245 parent studies. Performance of the signatures was evaluated on their ability to diagnose prevalent
246 TB disease at baseline and predict progression to incident TB disease through 15-month follow up.
247 For all analyses, HIV-infected (CORTIS-HR) and HIV-uninfected (CORTIS-01) participants were
248 considered independently. Diagnostic performance at baseline was assessed in all participants
249 enrolled in the CORTIS studies with available PAXgene samples. Thereafter, participants meeting
250 the primary prevalent TB endpoint definition, participants who did not attend further follow-up visits,
251 and participants randomized to the RISK11-positive 3HP group (CORTIS-01 only) were excluded
252 from the primary endpoint prognostic performance analysis. Participants were followed for up to 15
253 months; those who discontinued follow-up prior to 15 months and did not meet the primary
254 endpoint definition were censored at their final study visit or last negative sputum sample collection
255 but included in the prognostic analysis.

256

257 Due to enrichment of RISK11-positive individuals in the CORTIS-01 enrolled population, analyses
258 of signature performance required participant weighting to obtain estimates applicable to the
259 screened population, effectively upweighting RISK11-negative participants in the CORTIS-01
260 analyses (i.e. inverse probability weighting). Enrolment in the CORTIS-HR study and respiratory
261 pathobionts sub-study were independent of RISK11 status; analyses for these cohorts are not
262 weighted.

263

264 For evaluation of diagnostic performance in the CTBC, CORTIS-HR, and respiratory pathobionts
265 studies, area under the receiver operating characteristic curve (ROC) curve (AUC) was generated
266 using the pROC package³⁰ in R. Signature performance (AUC) between HIV-infected and HIV-
267 uninfected participants in the CTBC study was compared using methods described by DeLong et

268 al.³¹ Prognostic performance metrics through 15 months follow-up in CORTIS-HR were calculated
269 by use of non-parametric methods for time-dependent ROC curve analysis from survival data
270 using the R `survAM.estimate` function in the `survAccuracyMeasures` package³² in R. Binary
271 weighted ROC analysis was performed in the CORTIS-01 cohort to evaluate both diagnostic and
272 prognostic performance. In a post-hoc analysis, prognostic performance in CORTIS-01 was
273 qualitatively compared between 6, 12, and 15 months of follow-up for the primary endpoint by use
274 of identical methods.

275

276 There were no pre-defined score thresholds for the parsimonious signatures; optimal signature
277 score thresholds were calculated using the minimum Euclidean distance to 100% sensitivity and
278 specificity, i.e. the point closest to the top-left of the ROC curve, calculated for each cut-point (c) as
279 follows: $\sqrt{[(1 - \text{Sensitivity}_{(c)})^2 + (1 - \text{Specificity}_{(c)})^2]}$.³³ Signature diagnostic and prognostic accuracy
280 was also benchmarked against the minimal WHO TPP for a community-based TB triage or referral
281 test¹⁹ (specificity 70% or sensitivity 90%) and the minimal WHO TPP for an incipient TB test, to
282 predict progression to TB disease²⁰ (specificity 75% or sensitivity 75%), respectively.

283

284 Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) at each
285 threshold were calculated using binary endpoint indicators and standard formulae. Estimates of
286 PPV and NPV were computed based on the observed incidence of TB in the enrolled study
287 population. The 95% confidence intervals (CIs) on diagnostic and prognostic performance
288 estimates were calculated with a non-parametric percentile bootstrap with 10,000 resamples.³⁴
289 Bootstrap sampling was stratified by RISK11 status in the CORTIS-01 cohort, but not stratified in
290 the CTBC, CORTIS-HR, or respiratory pathobionts cohorts.

291

292 Signature score distribution was described using median and interquartile range. Differences
293 between groups were calculated using the Mann-Whitney U test and corrected for multiple
294 comparisons by use of the Benjamini-Hochberg Procedure.³⁵ Spearman's rank coefficient was
295 used to report correlation between signature scores; only samples with all assays passing were
296 include in the correlation matrices; and Roe1 and Roe3 signatures were multiplied by -1 to obtain a
297 positive correlation for all signatures. An alpha of <0.05 was considered significant in all analyses.

298

299 *Blinding*

300 Transcriptomic signature scores were measured by laboratory personnel who were blinded to
301 participant TB status. Participants and study staff responsible for TB screening were blinded to
302 transcriptomic signature scores. The statistical analysis team had access to clinical and
303 demographic data (including TB status), but were blinded to signature scores, to allow data
304 cleaning and preparation of analysis scripts prior to database lock. Signature scores and TB

305 microbiology results were maintained in different files, which were only integrated after the study
306 database had been cleaned and locked, and group allocations unblinded in CORTIS-01.

307

308 *Role of the funding sources*

309 The funders of this sub-study had no role in protocol development, study design, data collection,
310 data analysis, data interpretation, or writing of the report.

311 Results

312

313 *Transcriptomic signatures discriminate symptomatic pulmonary TB patients from healthy,*
314 *asymptomatic controls*

315 We translated measurement of eight parsimonious TB transcriptomic signatures to a microfluidic
316 RT- qPCR platform using TaqMan primer-probe assays for quantification of transcripts, using
317 previously described methods (**Table S1-6**). All new primer-probe assays passed qualification with
318 efficient linear amplification (**Table S3**). We then validated the performance of the signatures in the
319 CTBC study, a case-control cohort of HIV-uninfected and HIV-infected individuals with or without
320 pulmonary TB. Participants included 114 HIV-uninfected (53 TB cases and 61 asymptomatic
321 controls) and 86 HIV-infected (45 TB cases and 41 asymptomatic controls) adults (**Figure S1A**).
322 The performance of the Penn-Nicholson6 (RISK6) and RISK11 signatures in this cohort was
323 previously reported²², but is included here for comparison. We found that performance of all
324 signatures to discriminate between HIV-uninfected South African adults with TB from healthy
325 controls was excellent, with AUCs ranging from 0.89 (Thompson5, 95% CI 0.82–0.95) to 0.97
326 (RISK11 and Suliman4, both with 95% CI 0.93–1) (**Figure S2**). All signatures met the minimal
327 WHO triage test TPP benchmark criteria in this group (**Table S7A**). Discriminative performance
328 was generally lower in PLHIV, with AUCs ranging from 0.78 (Francisco2, 95% CI 0.68–0.88) to
329 0.96 (Suliman4, 95% CI 0.90–1), and was significantly worse ($p<0.05$) for RISK11 ($p=0.027$),
330 Francisco2 ($p=0.0095$), and Sweeney3 ($p=0.021$) (**Figure S2**). Only Penn-Nicholson6 and
331 Suliman4 met the minimal WHO triage test TPP benchmark criteria in PLHIV (**Table S7B**). Having
332 validated the signatures for microfluidic RT-qPCR in a case-control context, we next wished to
333 prospectively compare signature performance in a real-world setting.

334

335 *Recruitment of prospective community screening cohorts*

336 In the CORTIS-01 trial,¹¹ 20,207 adults were screened at five geographically distinct community
337 sites throughout South Africa; 16,248 HIV-uninfected individuals met inclusion for the CORTIS-01
338 study, of whom 2,923 participants were randomized and all were included in this parsimonious
339 signature sub-study (**Figure S1B** and **Table S8**). A further 963 adults were screened and 861
340 PLHIV met inclusion for the CORTIS-HR study¹² and all were included in this sub-study (**Figure**
341 **S1D** and **Table S9**). There were 61 HIV-uninfected (weighted prevalence 1.1%, 95% CI 0.8–1.6)
342 and 10 HIV-infected (prevalence 1.2%, 95% CI 0.6–2.1) baseline primary endpoint TB cases; over
343 80% of prevalent TB cases in the HIV-uninfected cohort, and 70% in the HIV-infected cohort, were
344 asymptomatic. Thereafter, 362 HIV-uninfected participants (350 in the 3HP arm, 10 lost to follow-
345 up, and 2 withdrawals) and 5 PLHIV (4 lost to follow-up and 1 withdrawal) were excluded from
346 analysis of prognostic performance for incident TB, such that 2,500 HIV-uninfected and 846 PLHIV
347 were included. Through 15 months follow-up, 24 HIV-uninfected participants (weighted incidence
348 1.1 per 100 person-years, 95% CI 0.6–1.5) and 9 PLHIV (incidence 1.0 per 100 person-years, 95%

349 CI 0.3–1.6) progressed to incident TB. Participants who discontinued follow-up prior to 15 months
350 were included in the prognostic assessment, but censored at their final study visit.

351

352 *Measurement of parsimonious transcriptomic signatures in the prospective cohorts*

353 The RISK11 signature assay panel (**Table S2**) was measured in all randomised HIV-uninfected
354 CORTIS-01 trial participants (N=2,923) and in all enrolled HIV-infected CORTIS-HR participants
355 who had baseline RNA samples available 857/861 (99.5%). RISK11 performance in these cohorts
356 was previously reported^{11,12}, but is included here for comparison without a pre-specified score
357 threshold. The parsimonious transcriptomic signature assay panel (**Table S3**) was measured in
358 2,904/2,923 (99.3%) HIV-uninfected and 858/861 (99.7%) HIV-infected participants who had
359 additional baseline RNA aliquots available. The parsimonious signature failure rate ranged from
360 1.4% (RISK6) to 25.3% (Suliman4) in the HIV-uninfected cohort and from 5.2% (RISK6) to 32.1%
361 (Suliman4) in PLHIV (**Tables S10-11**). Failed signature results for individual samples due to failed
362 RT-qPCR reactions were not repeated, and were excluded from analysis (details in **Supplemental**
363 **Results**).

364

365 Median signature scores for RISK11, Francisco2, Maertzdorf4, RISK6, Suliman4, Sweeney3, and
366 Thompson5 at baseline were highest amongst HIV-uninfected participants with symptomatic
367 (clinical) TB, and successively lower in participants with asymptomatic (sub-clinical) and incident
368 TB (participants who progressed to TB disease), and symptomatic and asymptomatic participants
369 without TB (**Figure 1**). The opposite was observed for the Roe1 and Roe3 signatures; this is
370 related to data processing rather than real differences in signature biology, and a similar trend
371 would be obtained by additively inverting the scores. A similar progression was observed for most
372 signatures amongst PLHIV, although differences in the TB spectrum were not as marked,
373 especially for Francisco2 and Sweeney3 (**Figure 2**).

374

375 Scores for all of the signatures were significantly correlated ($p > 0.05$; **Figure S3K and S4K**);
376 Parsimonious signature Spearman-rank correlation with RISK11 ranged from 0.41–0.90 in HIV-
377 uninfected and 0.25–0.88 in HIV-infected cohorts. Signatures with overlapping genes, such as (1)
378 Roe1, Roe3, and RISK11, or (2) Francisco2 and Sweeney3, were highly correlated (ρ 0.84–
379 0.96). The Thompson5 (RESPONSE5) treatment response monitoring signature had the poorest
380 correlation with other signatures in HIV-uninfected (0.22–0.56) and HIV-infected (0.16–0.46)
381 cohorts.

382

383 *Similar diagnostic performance in HIV-uninfected and HIV-infected individuals, and inferior*
384 *performance for detecting subclinical TB*

385 Diagnostic performance for primary endpoint prevalent TB was moderate for all signatures, ranging
386 from an AUC of 0.63 to 0.79 in the HIV-uninfected cohort (**Figure 1 and Table S10**). Primary

387 endpoint diagnostic performance estimates in PLHIV (AUC 0.65–0.88) were similar or exceeded
388 performance in the HIV-uninfected cohort for most signatures (**Figure 2 and Table S11**), except
389 the Thompson5 and Sweeney3 signatures, which appeared to perform poorly in PLHIV (lower 95%
390 confidence bound crossing 0.50). When disaggregated by TB symptom status, diagnostic
391 performance for detection of asymptomatic (subclinical) TB among all asymptomatic participants,
392 (AUCs ranging from 0.61 to 0.78) was inferior to performance for detection of symptomatic
393 (clinical) TB among all symptomatic participants (AUCs ranging from 0.85–0.98) for all signatures
394 in HIV-uninfected participants (**Figure 1**). AUC estimates for detecting symptomatic TB were also
395 higher for most signatures (RISK11, Maertzdorf4, Roe3, Suliman4, and Thompson5, with AUCs
396 ranging from 0.58–0.98) amongst HIV-infected participants (**Figure 2**) than for detecting
397 asymptomatic, subclinical TB (AUCs ranging from 0.59–0.86). However, because only two
398 symptomatic HIV-infected and eight symptomatic HIV-uninfected participants with prevalent TB
399 had available RNA, these exploratory results should be interpreted cautiously. As the majority of
400 healthy participants and TB cases were asymptomatic, the AUC estimates for the pooled primary
401 endpoint are very similar to estimates for the asymptomatic subgroup. Diagnostic performance for
402 the secondary endpoint was not qualitatively different to that of the primary endpoint for all
403 signatures in both HIV-uninfected and HIV-infected cohorts (**Figure S3-4**).

404

405 For the primary diagnostic endpoint and asymptomatic sub-group, no signatures met the minimal
406 WHO TPP benchmarks for a triage test (sensitivity 90% and specificity 70%) in the HIV-uninfected
407 cohort (**Figures 1 and Table S10**). However, five signatures (RISK11, RISK6, Roe1, Roe3 and
408 Suliman4) met the optimal WHO TPP benchmark (sensitivity 95% and specificity 80%) amongst
409 symptomatic participants, and the other four signatures (Francisco2, Maertzdorf4, Sweeney3, and
410 Thompson5) either approached or met the minimal WHO TPP in this sub-group (**Figure 1**).
411 Similarly amongst PLHIV, no signatures met the minimal WHO TPP benchmarks for a triage test
412 (sensitivity 90% and specificity 70%) for the primary diagnostic endpoint and asymptomatic sub-
413 group (**Figure 2 and Table S11**), however four signatures (RISK11, Maertzdorf4, Suliman4, and
414 Thompson5) met the optimal WHO triage test benchmarks in participants with TB symptoms
415 (**Figure 2**). Due to the small numbers of primary endpoint prevalent TB cases with evaluable
416 transcriptomic signature scores amongst PLHIV (two symptomatic and six asymptomatic),
417 precision around estimates was limited. For the primary diagnostic endpoint in the HIV-infected
418 cohort, the upper limits of the 95% confidence intervals of performance metrics were within the
419 bounds of the minimal WHO triage test criteria for most signatures, barring Francisco2, Sweeney3,
420 and Thompson5 (**Table S11**).

421

422 *Significant prognostic performance of signatures through 12 months in HIV-uninfected and 15-*
423 *months in HIV-infected cohorts*

424 We next evaluated transcriptomic signature prognostic performance for incident TB in all
425 participants without primary endpoint prevalent TB at baseline who attended one or more follow-up
426 visit. All signatures measured at enrolment had excellent performance for detecting HIV-uninfected
427 participants who progressed to primary endpoint incident TB disease through six months follow-up,
428 with AUCs ranging from 0.80–0.95 (**Figure 3 and Table S12**). Prognostic performance declined
429 through 15 months follow-up (AUCs 0.49–0.66) with only RISK6 showing significant discrimination
430 at this timepoint (AUC 0.66, 95% CI 0.51–0.82). Most signatures demonstrated good discrimination
431 (AUCs 0.63–0.80) up to 12 months post enrolment. In the HIV-infected CORTIS-HR cohort, there
432 were insufficient primary endpoint incident TB cases to evaluate prognostic performance prior to
433 15 months follow-up. Six of nine transcriptomic signatures were able to significantly differentiate
434 between incident TB cases and controls in the HIV-infected cohort through 15 months, with AUCs
435 ranging from 0.54–0.81 (**Figures 4 and Tables S13**). Lower 95% confidence bounds for the
436 Francisco2, Sweeney3, and Thompson5 signatures crossed 0.50 indicating that prognostic
437 performance at this timepoint was not significant. Prognostic performance through 15 months
438 follow-up for the secondary endpoint was not qualitatively different to the primary endpoint in either
439 cohort (**Figure S5-6**).

440

441 For primary endpoint incident TB, none of the signatures met the minimal WHO TPP benchmark
442 for a prognostic test (sensitivity 75% and specificity 75%) in the HIV-uninfected cohort through 15
443 months follow-up (**Figure 3 and Table S12**); the Roe3 signature came closest at its optimal cut-
444 point (sensitivity 70.0%, 95% CI 46.0-92.9; specificity 72.9%, 95% CI 71.1-74.7). However, through
445 six months follow-up, six of eight parsimonious signatures met the minimal benchmark. The
446 remaining two signatures, Suliman4 and Sweeney3, approached it with upper limits of the 95%
447 confidence intervals for prognostic estimates exceeding the benchmark bounds (**Table S12**). Only
448 RISK11 met the optimal WHO TPP benchmark for a prognostic test (sensitivity 90% and specificity
449 90%) through six months. Through 12 months follow-up, the upper limits of the 95% confidence
450 intervals for all signatures exceeded the minimal WHO TPP benchmark, but only the Roe3
451 signature (sensitivity 84.9%, 95% CI 55.0-100; specificity 75.4%, 95% CI 73.7-77.1) met the
452 benchmark. Amongst people living with HIV, only the Roe1 signature (sensitivity 83.8%, 95% CI
453 28.1-98.6; specificity 78.0%, 95% CI 74.5-81.0) met the minimal WHO TPP benchmark for a
454 prognostic test through 15 months follow-up (**Figure 4 and Table S13**), however the upper 95%
455 confidence interval bounds for six of eight of the other signatures (except Maertzdorf4 and
456 Sweeney3) also met or approximated this benchmark.

457

458 *Most TB signatures failed to differentiate participants with upper respiratory viral pathobionts from*
459 *those with TB disease*

460 Amongst participants with HIV we found that those without TB who had a detectable HIV plasma
461 viral load (≥ 100 copies/mL) had significantly higher ($p < 0.0001$; or conversely lower for Roe1 and

462 Roe3) transcriptomic signature scores than those with suppressed HIV plasma viral load (<100
463 copies/mL). The exception was Thompson5, the only signature that does not include ISGs¹⁸, which
464 was not affected by viral load ($p=0.87$; **Figure S7**). Among HIV-uninfected participants without TB,
465 scores for most signatures (except Francisco2 and Sweeney3) differed significantly ($p<0.05$)
466 between those with and without TB symptoms (**Figure 1**); we hypothesised that these differences
467 were due to the presence of other comorbid infections in the symptomatic participants.

468

469 We tested this hypothesis in a cohort 1,000 HIV-uninfected CORTIS-01 participants who were
470 consecutively enrolled into the respiratory pathobionts sub-study (**Figure S1C** and **Table S14**). All
471 participants were investigated, irrespective of symptoms, for upper respiratory tract pathobionts in
472 nasopharyngeal and oropharyngeal swabs using a multiplex bacteria and virus respiratory RT-
473 qPCR panel. Viral and/or bacterial pathobionts were detected in 7.4% (74/1,000) and 38.9%
474 (389/1,000) of participants respectively; with viral-bacterial co-detection in 3.3% (33/1,000)
475 participants.

476

477 TB transcriptomic signature scores were significantly higher ($p<0.05$; or conversely lower for Roe1
478 and Roe3) in participants with any viral pathobiont, or both viral and bacterial pathobionts,
479 compared to those with only bacterial, or no pathobionts, with the exception of Thompson5 (**Figure**
480 **5**). Most of the signatures significantly discriminated between viral and bacterial pathobionts, and
481 viral and no pathobionts, but were unable to differentiate bacterial from no pathobionts. We also
482 measured the Herberg2 signature²⁹, designed to discriminate between viral and bacterial infection
483 in febrile children, in the respiratory pathobionts cohort; this signature performed equivalently to the
484 other signatures in differentiating between the groups. Most of the upper respiratory bacteria
485 detected (*H influenzae* 21.3%, *S aureus* 10.2%, *S pneumoniae* 9.2%, *M catarrhalis* 5.8%) commonly
486 colonise the respiratory tract of healthy individuals, hence we are unable to determine the effect of
487 pathogenic bacteria on signature scores. Thompson5 was the only signature for which no
488 differences in scores were observed between participants with viral, bacterial, or no pathobionts,
489 and subsequently was not able to differentiate between these groups (**Figure 5**).

490

491 28.6% (286/1,000) of participants were co-enrolled into the respiratory pathobionts sub-study and
492 CORTIS-01 and consequently investigated for TB (**Figure S1C**). There were insufficient primary
493 endpoint TB cases for meaningful analysis. However, 11 secondary endpoint (≥ 1 sputum sample
494 positive for *Mtb*) prevalent TB cases (3.8%) were identified in CORTIS-01; 4/99 (4.0%) participants
495 with bacteria detected in the upper respiratory tract and 7/150 (4.7%) with no pathobionts detected.
496 No participants with viral upper respiratory pathobionts only ($n=41$), or mixed viral and bacterial
497 pathobionts ($n=33$), had prevalent TB. The presence of bacterial upper respiratory pathobionts did
498 not significantly affect TB diagnostic performance. Transcriptomic signatures differentiated
499 between participants with prevalent TB and those with no pathobionts detected, with AUCs

500 between 0.63 and 0.79, and between participants with prevalent TB and those with other bacterial
501 pathobionts with AUCs ranging from 0.60 to 0.81 (**Figure S8**). However, with the exception of
502 Thompson5 (AUC 0.73, 95% CI 0.51–0.93), none of the other signatures were able to differentiate
503 between participants with prevalent TB and those with viral upper respiratory pathobionts.

504 Discussion

505 We validated eight parsimonious TB transcriptomic signatures by microfluidic RT-qPCR and
506 prospectively evaluated their diagnostic and prognostic accuracy in two large community screening
507 cohorts of unselected HIV-uninfected and HIV-infected adults. We found that none of the
508 signatures met the WHO triage test TPP benchmarks¹⁹ for subclinical TB, although performance
509 for several signatures approached these thresholds. Parsimonious signature diagnostic
510 performance in adults with TB symptoms was superior to that in asymptomatic participants, with
511 most meeting or approaching the TPP benchmarks. In the HIV-uninfected cohort prognostic
512 accuracy for incident TB within six months of testing was excellent for virtually all parsimonious
513 signatures, while performance for TB within 12 months was moderate. Only one signature, RISK6,
514 had any statistically significant prognostic ability for incident TB within 15 months of testing.

515

516 This waning accuracy mirrors the finding of a short prognostic window after signature testing in the
517 meta-analysis by Gupta et al¹⁴, and supports the hypothesis that the timeframe of TB progression
518 from infection to clinical disease is highly heterogenous between individuals, ranging from months
519 to years.³⁶⁻³⁸ We postulate that the declining performance distal to signature measurement may be
520 due to low inflammatory activity in early disease stages, described as incipient TB. Individuals with
521 incipient TB may spontaneously control the infection and thus not progress to disease³⁷, resulting
522 in reduced specificity. In this regard, we suggest that the 2-year predictive window for a prognostic
523 test proposed in the WHO framework²⁰ be revisited. Transient viral infections may also increase
524 false positivity.¹⁷ Low sensitivity may reflect the high burden of population *Mtb* exposure and rate of
525 new infections in this endemic setting.

526

527 Performance of parsimonious signatures in PLHIV appeared to match or surpass performance in
528 participants without HIV, consistent with the findings of Turner and colleagues¹⁵. Most signatures
529 were able to differentiate between those who would progress to TB disease (progressors) through
530 15 months follow-up and non-progressors in the HIV-infected cohort, and the Roe1 signature met
531 the minimal WHO TPP benchmark for a prognostic test²⁰. The greater prognostic window of the
532 signatures measured at baseline in PLHIV may reflect prevalent TB cases missed at study
533 enrolment (possibly due to paucibacillary sputum), but detected further along the disease spectrum
534 during follow-up. At each study visit, participants underwent symptom screening with symptom-
535 guided TB investigations which would have missed asymptomatic disease at earlier timepoints.
536 However, all participants provided sputum samples for TB investigation at the end-of-study visits,
537 which may also explain the bulk of disease diagnosed at the month 15 visit. Most of the incident
538 TB cases in the HIV-infected cohort were detected after 12 months follow-up; this may be due to
539 the appearance of symptoms late in the disease course in immunosuppressed individuals, and as
540 a result, incident TB cases may have been missed by symptom screening at earlier visits. It is also
541 conceivable that the better performance in PLHIV is driven by ART-naïve individuals who have

542 increased risk of TB disease, but also have elevated signature scores (or lower for Roe1 and
543 Roe3) due to their higher HIV plasma viral loads. However, 74% (142/193) of ART-naïve
544 participants started ART during the study (**Table S9**), which would lower their risk of progression,
545 and increase “false” positivity. Unfortunately our study was underpowered to evaluate signature
546 performance stratified by viral load or ART status, however we postulate that higher signatures
547 scores in those with non-suppressed HIV plasma viral loads (**Figure S7**) would result in significantly
548 lower specificity, but equivalent or higher sensitivity.

549

550 We recently showed that elevated RISK11 signature scores in healthy individuals without TB return
551 to normal levels within three months irrespective of the use of TPT in the majority of individuals.¹⁷
552 The transient elevation of RISK11 may be due to self-clearance of *Mtb* infection in certain
553 individuals, but is likely due to other exogenous factors that temporarily affect transcriptomic
554 signature gene expression. Scores and performance of most parsimonious signatures, with the
555 exception of the Thompson5 signature, were affected by the presence of upper respiratory viral,
556 but not bacterial, pathobionts. Most transcriptomic signatures are primarily comprised of ISGs,
557 which are known to be induced by viral infections, including HIV. The Thompson5 signature, which
558 does not contain any ISGs, was unaffected by respiratory pathobionts or HIV. This supports the
559 hypothesis that exogenous factors, and in particular viral infections, have a large impact on TB
560 transcriptomic signature scores and performance due to induction of these genes; design of
561 transcriptomic signatures which do not predominantly consist of ISGs,^{39,40} or which use a
562 multinomial modelling⁴¹ approach to exclude viral infection, may address this shortcoming.

563

564 Given that this study was not designed to compare diagnostic and prognostic accuracy between
565 signatures, and the 95% confidence intervals of performance metrics for most signatures were
566 overlapping, we are hesitant to champion any particular signature. Several parsimonious
567 signatures performed at least as well as RISK11. Performance of most signatures is promising for
568 triage of symptomatic adults seeking care and PLHIV attending ART clinic, to rule out active
569 disease and guide further investigation, and for short-term (6-12 months) prognosis of TB disease
570 risk for targeted preventive therapy. Recent studies of 3HP have shown limited duration of efficacy
571 (9 months) for biomarker-guided preventive therapy in HIV-uninfected adults in South Africa¹¹, and
572 no additional benefit of universal annual retreatment of PLHIV on ART compared to a single
573 course⁴². Our results further suggest that a prognostic window greater than 12 months after testing
574 is unlikely to be of value in high transmission settings with associated risk of re-infection. This
575 implies that annual re-testing would likely be necessary if such signatures are to be included in TB
576 control strategies.⁴³ Parsimonious signature performance reported here warrants translation to
577 point-of-care devices for clinical implementation studies.

578

579 No signatures met the WHO triage test TPP accuracy benchmark for diagnosing asymptomatic
580 prevalent TB, which is a setback for community active case-finding efforts in endemic settings,
581 such as South Africa, where there is a high burden of undiagnosed sub-clinical disease.^{2-5,11,12}
582 However, we would note that these benchmarks were not intended for TB screening in a healthy
583 community setting, but rather “to test persons with any symptoms or risk factors suggestive of TB
584 who are seeking care”¹⁹, and thus the bar may have been too high for a strategy that seeks to find
585 subclinical TB cases. Currently, chest radiography is the only sufficiently accurate screening tool in
586 widespread use for detecting asymptomatic sub-clinical disease.²⁻⁵ Portable molecular screening
587 has also been proposed as a possible universal screening tool for active case-finding,⁷ but this
588 remains unaffordable in most settings. Given the recently recognised burden of asymptomatic TB
589 in endemic settings and lack of affordable and accessible active case-finding tools to detect early
590 and subclinical disease in community settings, we would propose that a new consensus framework
591 for the development of screening tests for asymptomatic TB is urgently needed. Such a framework
592 should also provide clear definitions of contentious concepts of asymptomatic “incipient” and “sub-
593 clinical” TB.^{44,45} We have previously demonstrated a sequential inflammatory TB disease process
594 ^{22,36,46}. The trend of increasing signature scores from individuals without TB disease, through early
595 or incipient (individuals who later progress to incident disease), sub-clinical, and clinical TB
596 disease observed in this study (**Figures 1-2**) succinctly illustrates the stages of disease
597 progression. Further trials are needed to determine whether earlier stages of TB progression
598 require a full course of curative treatment, or an abbreviated regimen such as 3HP.

599
600 The correlation between most signatures (with the exception of Thompson5), and fact that no
601 individual signature was significantly superior for diagnosis or prognosis, indicates they likely
602 measure the same or similar biological pathways. Our study would suggest that performance of
603 transcriptomic host-response signatures, based on discovery in active TB cases or progressor
604 cohorts, has reached an apex and that further signature discovery using similar conventional
605 methodology and study designs is unlikely to deliver significantly better diagnostic tools. What
606 could be done differently? First, we would argue the necessity for recruiting larger heterogenous
607 unselected prospective discovery cohorts, with TB cases representing a spectrum from sub-clinical
608 through clinical disease at prevalence rates that reflect the real epidemic, rather than carefully-
609 curated case-control studies with uniform and highly enriched TB cases and homogenous healthy
610 controls or inappropriate other diseases. In this study, all signatures performed superbly in the
611 CTBC case-control cohort, but performance dipped substantially in the real-world CORTIS studies.
612 Second, we have shown that parsimonious signatures perform at least as well as non-reduced
613 signatures such as RISK11; early translation of parsimonious signatures to near point-of-care
614 technology, such as RT-qPCR, would allow more rapid advancement along the developmental
615 pipeline. Third, few studies have incorporated clinical features (such as age, sex, body-mass
616 index, C-reactive protein, haemoglobin, monocyte-lymphocyte ratio, and HIV status or viral load)

617 into predictive host-response models, which may prove low-hanging fruit for improving signature
618 performance.^{47,48} Finally, selection of genes which remain stable on repeat measurements through
619 longitudinal follow-up in healthy individuals^{17,46}, and in individuals with common comorbid diseases
620 and infections, may enhance predictive utility. Modular (genes selected from distinct biological
621 pathways) or multinomial (multiple outcomes or covariates) modelling approaches to TB signature
622 discovery may help to mitigate the effect of exogenous factors on signature performance.^{39,41}

623

624 A major strength of this study was the prospective recruitment of large community cohorts of
625 unselected adults from multiple sites reflecting distinct patterns of *Mtb* exposure and rates of TB
626 disease in an endemic setting. Despite intensive community active case-finding with enrichment of
627 the HIV-uninfected study population for individuals at greatest risk of TB disease, sputum sample
628 collection from all enrolled participants at enrolment and end-of-study visits, and symptom-
629 triggered investigation during follow-up, there were relatively few prevalent and incident TB cases,
630 limiting power for analysis of diagnostic and prognostic performance. We also did not investigate
631 participants for extra-pulmonary TB, potentially missing cases amongst PLHIV. Another limitation
632 was the high Suliman4 failure rate, resulting in less precise performance estimates for this
633 signature. We also acknowledge that primer sequences selected for RT-qPCR may not be
634 equivalent to those used for microarray or in the Cepheid Xpert MTB Host Response prototype
635 cartridge^{49,50}. The large proportion of asymptomatic prevalent TB cases is a feature unique to this
636 cohort, and may prove valuable for future biomarker discovery. Recruitment was restricted to
637 South Africa, limiting generalisability of the results to other contexts; there is a need for similar
638 large prospective diagnostic validation cohorts in other TB endemic regions.

639

640 Several parsimonious TB transcriptomic signatures hold promise for triage of symptomatic adults
641 seeking care, screening of ART clinic attendees and other high-risk groups for further investigation,
642 and prediction of short-term risk of TB for initiation of targeted preventive therapy. Point-of-care
643 RT-qPCR testing platforms currently under development and in field implementation studies,^{49,50}
644 would bring these signatures from the laboratory bench to the clinic bedside.

645 **Author contributions**

646 SCM, AP-N, AF-G, MH, and TJS conceived the study. AP-N, SKM, MH, and TJS implemented
647 clinical studies, raised funds and/or provided the resources. MT, GW, KN, and GC were
648 responsible for all site-level activities, including recruitment, clinical management, and data
649 collection. SKM, MM, HM, MF, KH, and ME, and provided operational, technical, or laboratory
650 support and project management. SCM, ME, and ON processed samples and performed the
651 experiments. SCM, SKM, AF-G, and HM verified the underlying data. SCM and AF-G analysed
652 data. SCM, SKM, TJS, and MH interpreted results and wrote the first draft of the manuscript.
653 Members of the CTBC Study Team and the CORTIS Study Team performed clinical studies and
654 processed samples. All authors had full access to the data, confirm the integrity of the data and its
655 presentation, agree with its interpretation as discussed in the manuscript, and reviewed, revised,
656 and approved the manuscript before submission. The corresponding author had final responsibility
657 for the decision to submit for publication.

658

659 **Competing interests statement**

660 AP-N, GW, GC, TJS, and MH report grants from the Bill & Melinda Gates Foundation, during the
661 conduct of the study; AP-N and GW report grants from the South African Medical Research
662 Council, during the conduct of the study; GW and TJS report grants from the South African
663 National Research Foundation, during the conduct of the study. In addition, AP-N and TJS have
664 patents of the RISK11 and RISK6 signatures pending; GW has a patent “TB diagnostic markers”
665 (PCT/IB2013/054377) issued and a patent “Method for diagnosing TB” (PCT/IB2017/052142)
666 pending. All other authors had nothing to disclose.

667

668 **Data availability**

669 Deidentified signature scores, clinical metadata, and TB endpoint data will be made available with
670 publication in the supplemental material (**Tables S15-18**). The public PCR probe dataset and
671 metadata has been deposited in Zivahub (<https://doi.org/10.25375/uct.14999895>), an open access
672 data repository hosted by the University of Cape Town’s institutional data repository powered by
673 Figshare for Institutions.

674

675 **Funding**

676 The CTBC study was funded by the Strategic Health Innovation Partnerships (SHIP) Unit of the
677 South African Medical Research Council (SAMRC) with funds received from the South African
678 Department of Science and Technology. The CORTIS studies were funded by the Bill and Melinda
679 Gates Foundation (BMGF; OPP1116632, OPP1137034, and OPP1151915) and also the SHIP
680 Unit of the SAMRC with funds received from the South African Department of Science and
681 Technology. Respiratory infection assays were funded by the NIH (AI123780).

682

683 SCM is a recipient of PhD funding from the South African Medical Association (SAMA), the Fogarty
684 International Center of the National Institutes of Health (NIH) under Award Number D43
685 TW010559, the Harry Crossley Clinical Research Fellowship, and the South African Medical
686 Research Council (SAMRC) through its Division of Research Capacity Development under the
687 SAMRC Clinician Researcher Programme. The content is solely the responsibility of the authors
688 and does not necessarily represent the official views of SAMA, the NIH, the Harry Crossley
689 Foundation, or the SAMRC. The funders had no role in study design, data collection and analysis,
690 decision to publish, or preparation of the manuscript.

691 **References**

692

- 693 1. WHO. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
694 https://www.who.int/tb/publications/global_report/en/ (accessed October 15, 2020).
- 695 2. Onozaki I, Law I, Sismanidis C, Zignol M, Glaziou P, Floyd K. National tuberculosis
696 prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned.
697 *Tropical Medicine and International Health*. 2015;20(9):1128-45. doi: 10.1111/tmi.12534.
- 698 3. Frascella B, Richards AS, Sossen B, Emery JC, Odone A, Law I, et al. Subclinical
699 tuberculosis disease - a review and analysis of prevalence surveys to inform definitions,
700 burden, associations and screening methodology. *Clinical Infectious Diseases*. 2020. doi:
701 10.1093/cid/ciaa1402.
- 702 4. Law I, Floyd K, African TBPSG. National tuberculosis prevalence surveys in Africa, 2008-
703 2016: an overview of results and lessons learned. *Tropical Medicine and International*
704 *Health*. 2020;25(11):1308-27. doi: 10.1111/tmi.13485.
- 705 5. South African National Department of Health. The First National TB Prevalence Survey:
706 South Africa 2018. 2021. [www.knowledgehub.org.za/elibrary/first-national-tb-prevalence-](http://www.knowledgehub.org.za/elibrary/first-national-tb-prevalence-survey-south-africa-2018)
707 [survey-south-africa-2018](http://www.knowledgehub.org.za/elibrary/first-national-tb-prevalence-survey-south-africa-2018) (accessed May 22, 2021).
- 708 6. Harris M, Qi A, Jeagal L, Torabi N, Menzies D, Korobitsyn A, et al. A systematic review of
709 the diagnostic accuracy of artificial intelligence-based computer programs to analyze chest
710 x-rays for pulmonary tuberculosis. *PLoS ONE*. 2019;14(9):e0221339. doi:
711 10.1371/journal.pone.0221339.
- 712 7. Calligaro GL, Zijenah LS, Peter JG, Theron G, Buser V, McNerney R, et al. Effect of new
713 tuberculosis diagnostic technologies on community-based intensified case finding: a
714 multicentre randomised controlled trial. *Lancet Infectious Diseases*. 2017;17(4):441-50. doi:
715 10.1016/S1473-3099(16)30384-X.
- 716 8. Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, et al. Considerations
717 for biomarker-targeted intervention strategies for tuberculosis disease prevention.
718 *Tuberculosis (Edinb)*. 2018;109:61-8. doi: 10.1016/j.tube.2017.11.009.
- 719 9. Darboe F, Mbandi SK, Thompson EG, Fisher M, Rodo M, van Rooyen M, et al. Diagnostic
720 performance of an optimized transcriptomic signature of risk of tuberculosis in
721 cryopreserved peripheral blood mononuclear cells. *Tuberculosis (Edinb)*. 2018;108:124-6.
722 doi: 10.1016/j.tube.2017.11.001.
- 723 10. Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, et al. Detection
724 of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood
725 Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy. *Front*
726 *Microbiol*. 2019;10:1441. doi: 10.3389/fmicb.2019.01441.

- 727 11. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B,
728 et al. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled
729 trial. *Lancet Infectious Diseases*. 2021;21(3):354-65. doi: 10.1016/S1473-3099(20)30914-2.
- 730 12. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, et
731 al. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people
732 living with HIV: a prospective diagnostic and prognostic accuracy study. *Lancet glob health*.
733 2021;9(6):e841-e53. doi: 10.1016/S2214-109X(21)00045-0.
- 734 13. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis
735 diagnosis: A systematic comparison of 16 signatures. *PLoS Medicine*.
736 2019;16(4):e1002786. doi: 10.1371/journal.pmed.1002786.
- 737 14. Gupta RK, Turner CT, Venturini C, Esmail H, Rangaka MX, Copas A, et al. Concise whole
738 blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-
739 level pooled meta-analysis. *Lancet Respir Med*. 2020;8(4):395-406. doi: 10.1016/S2213-
740 2600(19)30282-6.
- 741 15. Turner CT, Gupta RK, Tsaliki E, Roe JK, Mondal P, Nyawo GR, et al. Blood transcriptional
742 biomarkers for active pulmonary tuberculosis in a high-burden setting: a prospective,
743 observational, diagnostic accuracy study. *Lancet Respir Med*. 2020;8(4):407-19. doi:
744 10.1016/S2213-2600(19)30469-2.
- 745 16. Mulenga H, Zauchenberger CZ, Bunyasi EW, Mbandi SK, Mendelsohn SC, Kagina B, et al.
746 Performance of diagnostic and predictive host blood transcriptomic signatures for
747 Tuberculosis disease: A systematic review and meta-analysis. *PLoS ONE*.
748 2020;15(8):e0237574. doi: 10.1371/journal.pone.0237574.
- 749 17. Mulenga H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, Mbandi SK, Fiore-Gartland
750 A, et al. Longitudinal dynamics of a blood transcriptomic signature of tuberculosis. 2021
751 (Submitted).
- 752 18. Thompson EG, Du Y, Malherbe ST, Shankar S, Braun J, Valvo J, et al. Host blood RNA
753 signatures predict the outcome of tuberculosis treatment. *Tuberculosis (Edinb)*.
754 2017;107:48-58. doi: 10.1016/j.tube.2017.08.004.
- 755 19. WHO. High-priority target product profiles for new tuberculosis diagnostics: report of a
756 consensus meeting. Geneva: World Health Organization, 2014.
757 www.who.int/tb/publications/tpp_report/en/ (accessed May 22, 2020).
- 758 20. WHO. Consensus Meeting Report: Development of a Target Product Profile (TPP) and a
759 framework for evaluation for a test for predicting progression from tuberculosis infection to
760 active disease. Geneva: World Health Organization, 2017.
761 <http://apps.who.int/iris/handle/10665/259176> (accessed May 22, 2020).
- 762 21. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD
763 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ*.
764 2015;351:h5527. doi: 10.1136/bmj.h5527.

- 765 22. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, et
766 al. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment
767 response. *Sci Rep*. 2020;10(1):8629. doi: 10.1038/s41598-020-65043-8.
- 768 23. Francisco NM, Fang YM, Ding L, Feng S, Yang Y, Wu M, et al. Diagnostic accuracy of a
769 selected signature gene set that discriminates active pulmonary tuberculosis and other
770 pulmonary diseases. *Journal of Infection*. 2017;75(6):499-510. doi:
771 10.1016/j.jinf.2017.09.012.
- 772 24. Maertzdorf J, McEwen G, Weiner J, 3rd, Tian S, Lader E, Schriek U, et al. Concise gene
773 signature for point-of-care classification of tuberculosis. *EMBO Molecular Medicine*.
774 2016;8(2):86-95. doi: 10.15252/emmm.201505790.
- 775 25. Suliman S, Thompson EG, Sutherland J, Weiner J, 3rd, Ota MOC, Shankar S, et al. Four-
776 Gene Pan-African Blood Signature Predicts Progression to Tuberculosis. *American Journal*
777 *of Respiratory and Critical Care Medicine*. 2018;197(9):1198-208. doi:
778 10.1164/rccm.201711-2340OC.
- 779 26. Roe JK, Thomas N, Gil E, Best K, Tsaliki E, Morris-Jones S, et al. Blood transcriptomic
780 diagnosis of pulmonary and extrapulmonary tuberculosis. *JCI Insight*. 2016;1(16):e87238.
781 doi: 10.1172/jci.insight.87238.
- 782 27. Roe J, Venturini C, Gupta RK, Gurry C, Chain BM, Sun Y, et al. Blood Transcriptomic
783 Stratification of Short-term Risk in Contacts of Tuberculosis. *Clinical Infectious Diseases*.
784 2020;70(5):731-7. doi: 10.1093/cid/ciz252.
- 785 28. Sweeney TE, Braviak L, Tato CM, Khatri P. Genome-wide expression for diagnosis of
786 pulmonary tuberculosis: a multicohort analysis. *Lancet Respir Med*. 2016;4(3):213-24. doi:
787 10.1016/S2213-2600(16)00048-5.
- 788 29. Herberg JA, Kafrou M, Wright VJ, Shailes H, Eleftherohorinou H, Hoggart CJ, et al.
789 Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial
790 vs Viral Infection in Febrile Children. *JAMA*. 2016;316(8):835-45. doi:
791 10.1001/jama.2016.11236.
- 792 30. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-
793 source package for R and S+ to analyze and compare ROC curves. *BMC Bioinformatics*.
794 2011;12:77. doi: 10.1186/1471-2105-12-77.
- 795 31. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
796 correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*.
797 1988;44(3):837-45. doi: 10.2307/2531595.
- 798 32. Zheng Y, Cai T, Brown M. Package 'survAccuracyMeasures'. 2014.
799 <http://mdbrown.github.io/survAccuracyMeasures/> (accessed May 22, 2020).
- 800 33. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two
801 criteria based on the receiver operating characteristic curve. *American Journal of*
802 *Epidemiology*. 2006;163(7):670-5. doi: 10.1093/aje/kwj063.

- 803 34. Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide
804 for medical statisticians. *Statistics in Medicine*. 2000;19(9):1141-64. doi:
805 10.1002/(sici)1097-0258(20000515)19:9<1141::Aid-sim479>3.0.Co;2-f.
- 806 35. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful
807 approach to multiple testing. *Journal of the Royal statistical society: series B*
808 (Methodological). 1995;57(1):289-300.
- 809 36. Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, et al.
810 Sequential inflammatory processes define human progression from *M. tuberculosis*
811 infection to tuberculosis disease. *PLoS Pathogens*. 2017;13(11):e1006687. doi:
812 10.1371/journal.ppat.1006687.
- 813 37. Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K, Schumacher SG, et al. Incipient and
814 Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.
815 *Clinical Microbiology Reviews*. 2018;31(4):e00021-18. doi: 10.1128/CMR.00021-18.
- 816 38. Scriba TJ, Mendelsohn SC. Headway made towards biosignatures for incipient
817 tuberculosis. *Lancet Respir Med*. 2020;8(4):328-30. doi: 10.1016/S2213-2600(19)30355-8.
- 818 39. Singhanian A, Verma R, Graham CM, Lee J, Tran T, Richardson M, et al. A modular
819 transcriptional signature identifies phenotypic heterogeneity of human tuberculosis
820 infection. *Nature Communications*. 2018;9(1):2308. doi: 10.1038/s41467-018-04579-w.
- 821 40. Esmail H, Lai RP, Lesosky M, Wilkinson KA, Graham CM, Horswell S, et al. Complement
822 pathway gene activation and rising circulating immune complexes characterize early
823 disease in HIV-associated tuberculosis. *Proceedings of the National Academy of Sciences*
824 of the United States of America. 2018;115(5):E964-E73. doi: 10.1073/pnas.1711853115.
- 825 41. Duffy FJ, Thompson EG, Scriba TJ, Zak DE. Multinomial modelling of TB/HIV co-infection
826 yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease
827 state. *PLoS ONE*. 2019;14(7):e0219322. doi: 10.1371/journal.pone.0219322.
- 828 42. Churchyard G, Cardenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, et al.
829 Effectiveness of 3HP annually vs once for HIV-positive people: The WHIP3TB Trial [CROI
830 Abstract 143]. In Special Issue: Abstracts From the 2020 Conference on Retroviruses and
831 Opportunistic Infections. *Top Antivir Med*. 2020;28(1).
- 832 43. Sumner T, Mendelsohn SC, Scriba TJ, Hatherill M, White R. The impact of blood
833 transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV:
834 a mathematical modelling study. 2021 (Submitted).
- 835 44. Kendall EA, Shrestha S, Dowdy DW. The Epidemiological Importance of Subclinical
836 Tuberculosis. A Critical Reappraisal. *American Journal of Respiratory and Critical Care*
837 *Medicine*. 2021;203(2):168-74. doi: 10.1164/rccm.202006-2394PP.
- 838 45. Pierce CW. Subclinical Tuberculosis: Some Flies in the Ointment. *American Journal of*
839 *Respiratory and Critical Care Medicine*. 2021. doi: 10.1164/rccm.202101-0227LE.

- 840 46. Zak DE, Penn-Nicholson A, Scriba TJ, Thompson E, Suliman S, Amon LM, et al. A blood
841 RNA signature for tuberculosis disease risk: a prospective cohort study. *Lancet*.
842 2016;387(10035):2312-22. doi: 10.1016/S0140-6736(15)01316-1.
- 843 47. Sivakumaran D, Jenum S, Vaz M, Selvam S, Ottenhoff THM, Haks MC, et al. Combining
844 host-derived biomarkers with patient characteristics improves signature performance in
845 predicting tuberculosis treatment outcomes. *Commun Biol*. 2020;3(1):359. doi:
846 10.1038/s42003-020-1087-x.
- 847 48. Mendelsohn SC, Mbandi SK, Hatherill M, Scriba TJ. Blood transcriptional signatures for
848 tuberculosis testing. *Lancet Respir Med*. 2020;8(4):330-1. doi: 10.1016/S2213-
849 2600(20)30045-X.
- 850 49. Sodersten E, Ongarello S, Mantsoki A, Wyss R, Persing DH, Banderby S, et al. Diagnostic
851 Accuracy Study of a Novel Blood-Based Assay for Identification of Tuberculosis in People
852 Living with HIV. *Journal of Clinical Microbiology*. 2021;59(3). doi: 10.1128/JCM.01643-20.
- 853 50. Moreira FMF, Verma R, Pereira Dos Santos PC, Leite A, da Silva Santos A, de Araujo
854 RCP, et al. Blood-based host biomarker diagnostics in active case finding for pulmonary
855 tuberculosis: A diagnostic case-control study. *EClinicalMedicine*. 2021;33:100776. doi:
856 10.1016/j.eclinm.2021.100776.
- 857
- 858

859 **Figure legends**

860

861 **Figure 1: Parsimonious signature diagnostic performance for prevalent TB and signature**
862 **score distributions in people without HIV**

863 Paired receiver operating characteristic (ROC) curves and box-and-whisker plots for the (A-B)
864 Darboe11 (RISK11), (C-D) Francisco2, (E-F) Maertzdorf4 (DIAG4), (G-H) Penn-Nicholson6
865 (RISK6), (I-J) Roe1 (BATF2), (K-L) Roe3, (M-N) Suliman4 (RISK4), (O-P) Sweeney3, and (Q-R)
866 Thompson5 (RESPONSE5) signatures in the CORTIS-01 study of people without HIV.
867 The ROC curves depict diagnostic performance (area under the curve, AUC, with 95% CI) of the
868 parsimonious signatures for the primary endpoint (1' Endpoint), i.e. TB diagnosed on two or more
869 liquid culture-positive or Xpert MTB/RIF-positive sputum samples. The ROC curves show
870 participants with symptomatic clinical prevalent TB versus symptomatic controls (Symptom+), and
871 participants with asymptomatic, subclinical prevalent TB versus asymptomatic controls (Symptom-
872). The shaded areas represent the 95% CIs. The solid box depicts the optimal criteria (95%
873 sensitivity and 80% specificity) and the dashed box depicts the minimal criteria (90% sensitivity
874 and 70% specificity) set out in the WHO Target Product Profile for a triage test.¹⁹
875 The box-and-whisker plots depict signature score (measured at enrolment) distribution by
876 symptom status (each dot represents a participant) in asymptomatic and symptomatic participants
877 with no TB, participants who progressed to incident TB, and participants with prevalent subclinical
878 (asymptomatic) and clinical (symptomatic) TB. Prevalent and incident TB comprised all primary
879 endpoint cases. Symptoms were recorded at the time of enrolment for participants without TB and
880 those with prevalent TB. p values for comparison of median signature scores between groups in
881 box-and-whisker plots were calculated with the Mann-Whitney *U* test and corrected for multiple
882 comparisons by use of the Benjamini-Hochberg Procedure.³⁵ Boxes depict the IQR, the midline
883 represents the median, and the whiskers indicate the IQR \pm (1.5 \times IQR).
884 (S) Summary of signature diagnostic performance in order of primary endpoint AUC estimates.
885 The diagnostic AUC estimates in symptomatic and asymptomatic participant sub-groups are also
886 shown. The midline indicates the AUC estimate, the error bars indicate the 95% CIs, and the black
887 dotted line indicates the lower bound of the 95% CI for the best performing signature for the
888 primary endpoint.

889

890 **Figure 2: Parsimonious signatures diagnostic performance for prevalent TB and signature**
891 **score distributions in people living with HIV.**

892 Paired receiver operating characteristic (ROC) curves and box-and-whisker plots for the (A-B)
893 Darboe11 (RISK11), (C-D) Francisco2, (E-F) Maertzdorf4 (DIAG4), (G-H) Penn-Nicholson6
894 (RISK6), (I-J) Roe1 (BATF2), (K-L) Roe3, (M-N) Suliman4 (RISK4), (O-P) Sweeney3, and (Q-R)
895 Thompson5 (RESPONSE5) signatures in the CORTIS-HR study of people living with HIV.

896 The ROC curves depict diagnostic performance (area under the curve, AUC, with 95% CI) of the
897 parsimonious signatures for TB diagnosed for the primary endpoint (1' Endpoint), i.e. TB
898 diagnosed on two or more liquid culture-positive or Xpert MTB/RIF-positive sputum samples. The
899 ROC curves show participants with symptomatic clinical prevalent TB versus symptomatic controls
900 (Symptom+), and participants with asymptomatic subclinical prevalent TB versus asymptomatic
901 controls (Symptom-). The shaded areas represent the 95% CIs. The solid box depicts the optimal
902 criteria (95% sensitivity and 80% specificity) and the dashed box depicts the minimal criteria (90%
903 sensitivity and 70% specificity) set out in the WHO Target Product Profile for a triage test.¹⁹
904 The box-and-whisker plots depict signature score (measured at enrolment) distribution by
905 symptom status (each dot represents a participant) in asymptomatic and symptomatic participants
906 with no TB, participants who progressed to incident TB, and participants with prevalent subclinical
907 (asymptomatic) and clinical (symptomatic) TB. Prevalent and incident TB comprised all primary
908 endpoint cases. Symptoms were recorded at the time of enrolment for participants without TB and
909 those with prevalent TB. p values for comparison of median signature scores between groups in
910 box-and-whisker plots were calculated with the Mann-Whitney *U* test and corrected for multiple
911 comparisons by use of the Benjamini-Hochberg Procedure.³⁵ Boxes depict the IQR, the midline
912 represents the median, and the whiskers indicate the IQR \pm (1.5 \times IQR).
913 (S) Summary of signature diagnostic performance in order of primary endpoint AUC estimates.
914 The diagnostic AUC estimates in symptomatic and asymptomatic participant sub-groups are also
915 shown. The midline indicates the AUC estimate, the error bars indicate the 95% CIs, and the black
916 dotted line indicates the lower bound of the 95% CI for the best performing signature for the
917 primary endpoint. The black dashed line (Figure 2S only) indicates an AUC cut-off of 0.5.

918

919 **Figures 3: Parsimonious signature prognostic performance for incident TB in people**
920 **without HIV**

921 Receiver operating characteristic curves depicting prognostic performance (area under the curve,
922 AUC, with 95% CI) of the (A) Darboe11 (RISK11), (B) Francisco2, (C) Maertzdorf4 (DIAG4), (D)
923 Penn-Nicholson6 (RISK6), (E) Roe1 (BATF2), (F) Roe3, (G) Suliman4 (RISK4), (H) Sweeney3,
924 and (I) Thompson5 (RESPONSE5) signatures for incident TB diagnosed on two or more liquid
925 culture-positive or Xpert MTB/RIF-positive sputum samples (primary endpoint) through 6, 12, and
926 15 months follow-up in the CORTIS-01 study of people without HIV.

927 The shaded areas represent the 95% CIs. The solid box depicts the optimal criteria (90%
928 sensitivity and 90% specificity) and the dashed box depicts the minimal criteria (75% sensitivity
929 and 75% specificity) set out in the WHO Target Product Profile for an incipient TB test.²⁰

930 (J) Summary of signature prognostic performance in order of primary endpoint AUC estimates
931 through 12 months follow-up. The prognostic AUC estimates through 6 and 15 months are also
932 shown. The midline indicates the AUC estimate, the error bars indicate the 95% CIs, and the black
933 dashed line indicates an AUC cut-off of 0.5.

934

935 **Figures 4: Parsimonious signature prognostic performance for prevalent TB in people living**
936 **with HIV**

937 Receiver operating characteristic curves depicting prognostic performance (area under the curve,
938 AUC, with 95% CI) of the (A) Darboe11 (RISK11), (B) Francisco2, (C) Maertzdorf4 (DIAG4), (D)
939 Penn-Nicholson6 (RISK6), (E) Roe1 (BATF2), (F) Roe3, (G) Suliman4 (RISK4), (H) Sweeney3,
940 and (I) Thompson5 (RESPONSE5) signatures for incident TB diagnosed on two or more liquid
941 culture-positive or Xpert MTB/RIF-positive sputum samples (primary endpoint) through 15 months
942 follow-up in the CORTIS-HR study of people living with HIV.

943 The shaded areas represent the 95% CIs. The solid box depicts the optimal criteria (90%
944 sensitivity and 90% specificity) and the dashed box depicts the minimal criteria (75% sensitivity
945 and 75% specificity) set out in the WHO Target Product Profile for an incipient TB test.²⁰

946 (J) Summary of signature prognostic performance in order of primary endpoint AUC estimates
947 through 15 months follow-up. The midline indicates the AUC estimate, the error bars indicate the
948 95% CIs, the red dotted line indicates the lower bound of the 95% CI for the best performing
949 signature for the primary endpoint, and the black dashed line indicates an AUC cut-off of 0.5.

950

951 **Figures 5: Parsimonious signature performance for differentiating participants with viral or**
952 **bacterial upper respiratory tract pathobionts, and those without any pathobionts**

953 Paired receiver operating characteristic (ROC) curves and box-and-whisker plots for the (A-B)
954 Darboe11 (RISK11), (C-D) Francisco2, (E-F) Herberg2, (G-H) Maertzdorf4 (DIAG4), (I-J) Penn-
955 Nicholson6 (RISK6), (K-L) Roe1 (BATF2), (M-N) Roe3, (O-P) Suliman4 (RISK4), (Q-R) Sweeney3,
956 and (S-T) Thompson5 (RESPONSE5) signatures in all participants without prevalent TB in the
957 respiratory pathobionts sub-study (11 participants with secondary endpoint prevalent TB
958 excluded).

959 The box-and-whisker plots depict signature score distributions in participants with no upper
960 respiratory pathobionts (n=563), bacterial upper respiratory pathobionts only (n=352), viral upper
961 respiratory pathobionts only (n=41), both viral and bacterial upper respiratory pathobionts (n=33). p
962 values for comparison of median signature scores between groups in box-and-whisker plots were
963 calculated with the Mann-Whitney *U* test and corrected for multiple comparisons by use of the
964 Benjamini-Hochberg Procedure.³⁵ Only p-values below 0.1 are shown. Each dot represents a
965 participant. Boxes depict the IQR, the midline represents the median, and the whiskers indicate the
966 $IQR \pm (1.5 \times IQR)$.

967 The ROC curves depict performance (area under the curve, AUC, with 95% CI) of the
968 parsimonious signatures in differentiating between participants with viral upper respiratory
969 pathobionts and participants with bacterial upper respiratory pathobionts, between participants with
970 viral pathobionts and those with no pathobionts, or between participants with bacterial pathobionts
971 and those with no pathobionts. The shaded areas represent the 95% CIs.

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

